
|Videos|July 13, 2017
Results for Durvalumab in the Second-Line Treatment of NSCLC
Author(s)Martin Gutierrez, MD
Martin Gutierrez, MD, director, drug discovery/phase I unit, medical oncologist, thoracic and gastrointestinal oncology, John Theurer Cancer Center, discusses results for durvalumab (Imfinzi) for the treatment of non-small cell lung cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies
3
In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade
4
Real-World Analysis Explores GLP-1 Use and Overall Survival
5










































